Optimized background therapy (OBT)
Sponsors
ViiV Healthcare, United BioPharma
Conditions
HIV InfectionsHIV-1 Infection
Phase 2
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects
CompletedNCT00098748
Start: 2004-11-30End: 2009-04-30Updated: 2010-12-07
UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients
NCT03164447
Start: 2023-12-31End: 2024-05-31Target: 10Updated: 2023-04-24